Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CSPC Pharmaceutical Group ( (HK:1093) ) has provided an announcement.
CSPC Pharmaceutical Group Limited has disclosed an updated list of its board of directors, confirming a large slate of executive and independent non-executive directors led by Chairman Cai Dong Chen and Vice-Chairman and Chief Executive Officer Dr. Cai Lei. The company also detailed the composition of its key board committees, designating roles for audit, nomination and remuneration oversight, with independent directors such as Wang Bo, Chen Chuan, Au Chun Kwok Alan and Li Quan taking on committee chairmanships and memberships, underscoring CSPC’s emphasis on corporate governance and board oversight as it manages its strategic and operational decisions.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company engaged in the research, development, manufacturing and sale of pharmaceutical products. Listed on the Hong Kong Stock Exchange, the group operates across key therapeutic areas and serves both domestic and international healthcare markets.
Average Trading Volume: 121,701,023
Technical Sentiment Signal: Buy
Current Market Cap: HK$86.5B
Find detailed analytics on 1093 stock on TipRanks’ Stock Analysis page.